Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06945419 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
A Phase 1 study of Healthy and Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 201
- Enrollment target
- 5
- Study locations
NCT06945419: Recruiting Phase 1 study of Healthy and Obesity, sponsored by Eli Lilly and Company.
NCT06945419 is a Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 201 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06945419, a Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 201 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY4086940
Study Locations (5)
Florida
- Fortrea Clinical Research Unit - Daytona Beach
- Clinical Pharmacology of Miami - Miami
Texas
- Fortrea Clinical Research Unit - Dallas
- Endeavor Clinical Trials - San Antonio
Other
- Lilly Centre for Clinical Pharmacology - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What NCT06945419 shows while recruiting
NCT06945419 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower).
The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06945419 lists 5 locations in 3 states (Florida, Texas, Other).
Frequently Asked Questions
What is clinical trial NCT06945419 about?
NCT06945419 is a clinical study titled "A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes". The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up t...
What is the current status of trial NCT06945419?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 201 participants. The study started on 2025-04-23. Estimated completion is 2026-04.
What conditions does trial NCT06945419 study?
This clinical trial studies the following conditions: Healthy, Obesity, Type 2 Diabetes, Overweight.
What interventions are being tested in trial NCT06945419?
The interventions under investigation include: Placebo (DRUG), LY4086940 (DRUG).
Who is sponsoring clinical trial NCT06945419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06945419 being conducted?
This trial has 5 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06945419's enrollment target sits among peer trials
201 117th of 1090 higher than 974 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI